Since ESR1, ESR2 and PGR impact the fuction of estrogen and progesterone, we hypothesized that the presence of functional polymorphisms in these genes would be associated with MS-AEs among postmenopausal breast cancer survivors on AI therapy. This evidence concerns the gene ESR2 and myeloid sarcoma.